MA55821B1 - Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression - Google Patents

Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression

Info

Publication number
MA55821B1
MA55821B1 MA55821A MA55821A MA55821B1 MA 55821 B1 MA55821 B1 MA 55821B1 MA 55821 A MA55821 A MA 55821A MA 55821 A MA55821 A MA 55821A MA 55821 B1 MA55821 B1 MA 55821B1
Authority
MA
Morocco
Prior art keywords
treatment
ht2a
depression
relates
ht2a antagonists
Prior art date
Application number
MA55821A
Other languages
English (en)
Other versions
MA55821A (fr
Inventor
Jesper Langgaard Kristensen
Anders Asbjørn Jensen
Emil Märcher-Rørsted
Sebastian Leth-Petersen
Original Assignee
Lophora ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lophora ApS filed Critical Lophora ApS
Publication of MA55821A publication Critical patent/MA55821A/fr
Publication of MA55821B1 publication Critical patent/MA55821B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne des antagonistes des récepteurs 5-ht2a de la sérotonine et leurs utilisations médicales. Selon un aspect, l'invention concerne des agonistes 5-ht2a de formule (i). Selon un autre aspect, l'invention concerne des antagonistes 5-ht2a destinés à être utilisés dans le traitement d'un trouble dépressif, en particulier un antagoniste 5-ht2a destiné à être utilisé dans le traitement des dépressions pharmacorésistantes.
MA55821A 2019-11-07 2020-11-06 Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression MA55821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19207578 2019-11-07
PCT/EP2020/081357 WO2021089824A1 (fr) 2019-11-07 2020-11-06 Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression

Publications (2)

Publication Number Publication Date
MA55821A MA55821A (fr) 2022-05-04
MA55821B1 true MA55821B1 (fr) 2023-08-31

Family

ID=68502828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55821A MA55821B1 (fr) 2019-11-07 2020-11-06 Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression

Country Status (21)

Country Link
US (3) US11246860B2 (fr)
EP (1) EP3962601B1 (fr)
JP (1) JP7566021B2 (fr)
CN (1) CN114761083B (fr)
AU (1) AU2020379225B2 (fr)
BR (1) BR112022008037A2 (fr)
CA (1) CA3156513A1 (fr)
DK (1) DK3962601T3 (fr)
ES (1) ES2953926T3 (fr)
FI (1) FI3962601T3 (fr)
HR (1) HRP20230856T1 (fr)
HU (1) HUE062369T2 (fr)
IL (1) IL292585B2 (fr)
LT (1) LT3962601T (fr)
MA (1) MA55821B1 (fr)
MD (1) MD3962601T2 (fr)
PL (1) PL3962601T3 (fr)
PT (1) PT3962601T (fr)
SI (1) SI3962601T1 (fr)
WO (1) WO2021089824A1 (fr)
ZA (1) ZA202204809B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20260044248A (ko) 2020-08-18 2026-04-01 사이빈 아이알엘 리미티드 치료 펜에틸아민 조성물 및 사용 방법
JP2024516827A (ja) 2021-04-30 2024-04-17 マインド メディシン， インコーポレイテッド Ｌｓｄ塩結晶形態
WO2022234010A1 (fr) * 2021-05-06 2022-11-10 Lophora ApS Sels d'addition d'acide de (s)-3-(2,5-diméthoxy-4-(trifluorométhyl)phényl)pipéridine et de (s)-3-(2-méthoxy-5-(méthylthio)-4-(trifluorométhyl)phényl)pipéridine, leurs polymorphes spécifiques et leurs procédés de fabrication
IL309842A (en) * 2021-07-26 2024-02-01 Univ Louisiana State Compounds and methods for treating situations where the response depends on 5-HT2
AU2022331315B2 (en) 2021-08-19 2025-10-16 Definium Therapeutics US, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
WO2024181024A1 (fr) * 2023-03-02 2024-09-06 本田技研工業株式会社 Composition
WO2025008804A1 (fr) * 2023-07-06 2025-01-09 M – Path Biopharma Ltd. Polythérapie pour apporter des améliorations aux effets secondaires d'un traitement par inhibiteurs des récepteurs des œstrogènes
WO2026073180A2 (fr) * 2024-09-30 2026-04-02 Revolution Medicines, Inc. Synthèse d'inhibiteurs de ras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608101B1 (en) 2000-06-20 2003-08-19 Atherogenics, Inc. 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression

Also Published As

Publication number Publication date
HRP20230856T1 (hr) 2023-11-10
US11246860B2 (en) 2022-02-15
US20210137908A1 (en) 2021-05-13
MD3962601T2 (ro) 2023-10-31
US11642336B2 (en) 2023-05-09
DK3962601T3 (da) 2023-09-04
WO2021089824A1 (fr) 2021-05-14
US11633390B2 (en) 2023-04-25
HUE062369T2 (hu) 2023-10-28
SI3962601T1 (sl) 2023-10-30
ES2953926T3 (es) 2023-11-17
FI3962601T3 (fi) 2023-08-09
CA3156513A1 (fr) 2021-05-14
MA55821A (fr) 2022-05-04
BR112022008037A2 (pt) 2022-07-12
PT3962601T (pt) 2023-08-28
CN114761083B (zh) 2024-02-13
EP3962601B1 (fr) 2023-05-31
CN114761083A (zh) 2022-07-15
JP7566021B2 (ja) 2024-10-11
US20210330658A1 (en) 2021-10-28
IL292585A (en) 2022-06-01
JP2023501275A (ja) 2023-01-18
AU2020379225A1 (en) 2022-05-26
IL292585B2 (en) 2023-08-01
PL3962601T3 (pl) 2023-10-09
US20220062257A1 (en) 2022-03-03
ZA202204809B (en) 2022-11-30
IL292585B1 (en) 2023-04-01
AU2020379225B2 (en) 2026-03-26
EP3962601A1 (fr) 2022-03-09
LT3962601T (lt) 2023-09-11

Similar Documents

Publication Publication Date Title
MA57972B1 (fr) Inhibiteurs de parp1
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA45020A (fr) Dérivés sulfonamides aromatiques
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
BR112018005163A2 (pt) terapia de combinação de cenicriviroc para o tratamento de fibrose
JOP20230036A1 (ar) نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA49127B1 (fr) Dérivés d'indole n-substitués
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA44037B1 (fr) Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
FR3065642B1 (fr) Utilisation de 20-hydroxyecdysone et ses derives dans le traitement des myopathies
MA29723B1 (fr) Composes
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
GEAP202415903A (en) Antimalarial agents
PH12021550549A1 (en) Dp antagonist